Citius Pharmaceuticals Inc. (CTXR)
CTXR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.4760
-3.41% on the day
Market cap
$13.1M
Nano cap
Revenue
No annual revenue filed since the period ending 2022-09-30
Net income
No annual revenue filed since the period ending 2022-09-30
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | CTXR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001506251 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
No annual revenue filed since the period ending 2022-09-30.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document REGISTRATION STATEMENT | S-3 | 2026-05-22 |
| Latest annual report AMENDMENT NO. 1 TO FORM 10-K | 10-K/A | 2026-01-28 |
| Latest quarterly / interim QUARTERLY REPORT | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-08-21 |
| Latest proxy DEFINITIVE ADDITIONAL MATERIALS | DEFA14A | 2026-02-24 |
Source: SEC EDGAR submissions feed, 636 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLRB | Cellectar Biosciences Inc. | $1.39 | -2.80% | $13.1M |
| BFRI | Biofrontera Inc. | $0.8922 | -3.56% | $13.3M |
| LPCN | Lipocine Inc. | $1.62 | -2.41% | $13.4M |
| GTBP | GT Biopharma Inc. | $6.50 | -4.41% | $13.4M |
| HIND | Vyome Holdings Inc. | $1.97 | -1.99% | $13.8M |
| ALLR | Allarity Therapeutics Inc. | $0.8699 | +1.14% | $13.8M |
| TVRD | Tvardi Therapeutics Inc. | $1.04 | -1.89% | $13.9M |
| KTTA | Pasithea Therapeutics Corp. | $0.4238 | -5.30% | $14.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier